NEW YORK, Feb. 7 (GenomeWeb News) - Serologicals has signed an agreement with Cellumen to commercialize a cytotoxicity profiling panel and services, Serologicals said today.
The system will be designed with cellular assay reagents from Serologicals' Chemicon and Upstate units and with Cellumen's system cell biology approach, the company said in a statement.
Chemicon will focus on the development and production of assays and panels, while Cellumen will focus on their use on profiling services.
The companies will market the products jointly.
No additional details were provided.